Abstract 933P
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine malignancy with a higher case-fatality rate than melanoma. The prognosis of MCC is complex and depends on many factors. In this study, we aimed to develop predictive survival models using machine learning (ML) algorithms and statistical techniques for patients with head and neck MCC.
Methods
Using a cohort of 1,372 patients diagnosed with MCC of the head and neck region in the United States between 2000 to 2019 sourced from the Surveillance, Epidemiology, and End Results (SEER) Program, we developed and evaluated a cox-proportional hazards (CPH) regression model, nine classification and regression ML models, and two ML-based survival models. Models were built with a total of 20 features, including demographic, cancer-related and treatment/surgery-related variables. Pre-processing, hyperparameter tuning, classification, regression, survival analyses, and model evaluations were performed using ‘scikit-learn', ‘scikit-survival', and ‘lifelines' packages on Python 3.80.
Results
The mean age of patients was (66.0). Most cases were diagnosed in stage I (n=723, 52.7%). Multivariate CPH model yielded a Concordance-Index (C-Index) = 0.700 on the test set, outperforming both random forest survival (C-Index = 0.591) and survival tree (C-Index = 0.582) algorithms. Of the nine classification models, gradient boosting classifier predicted the most accurate 2-year (AUC = 0.75; accuracy= 0.71) and 5-year (AUC = 0.75; accuracy = 0.68) survival. Additionally, the ridge- and lasso-regularized linear models performed the most accurate regression (RMSE = 1182.84, R2 = 0.2259; RMSE = 1184.70, R2 = 0.2234, respectively), and the gradient boosting regressor had acceptable predictions (RMSE = 1189.64, R2 = 0.2170) on test sets. According to the Shapley Additive Explanations (SHAP) value analysis, the most critical feature of these regression models was age, followed by sex and AJCC stage.
Conclusions
This study found that machine learning and statistical models provide reliable survival predictions for head and neck Merkel cell carcinoma, with models like gradient boosting classifiers having acceptable outputs, especially for 2-year survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03